An evening dedicated towards understanding the latest advancements in management of Hepatocellular Carcinoma ( #HCC ) at the #AIGHospitals . We were thrilled to have Dr. Amit G Singal (Amit G Singal) sharing insights about #atezolizumab plus #bevacizumab in treatment of #LiverCancer .…

El Ministerio para la Salud informó que recibió una alerta sanitaria emitida por el Instituto Nacional de Higiene “Rafael Rangel” sobre el producto Tecentriq (Atezolizumab) 60 mg/ml concentrado para solución e infusión P.B 1470/23, número de lote H0346b07.

El ente ministerial…

ฅNya! Here's the latest 🗞 from [ Nature Communications ]: ' CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials' 🔗: nature.com/articles/s4146…

Back to back Heather McArthur, MD, MPH European Breast Cancer Conference (EBCC-14) #EBCC14 Final analysis of ALEXANDRA/ IMpassion030 Adjuvant atezolizumab for stage ll/III TNBC

#TrialTuesday : STELLAR-303 is a phase III #clinicaltrial evaluating the novel tyrosine kinase inhibitor XL092 (zanzalintinib) + atezolizumab versus regorafenib in patients with metastatic #colorectalcancer ➡️ jeffersonhealth.org/clinical-speci…
#ColorectalCancerAwarenessMonth Daniel Lin, MD

ADAs e IO

Presencia de atezolizumab ADAs en HCC, perdida de respuesta

La cuestión ahora es:

¿Pérdida de la eficacia al bloqueo PD1/PDL1
o
¿Fallo secundario y cambio a otra IO?

Experiencia local sobre la aparición de ADAs (se confirma lo publicado)

A step forward in implementing anti-PD(L)1 across growing not otherwise specified of indications? - Jarushka Naidoo
JTO & JTO CRR OncoAlert
oncodaily.com/64340.html

#AdvancedNSCLC #Atezolizumab #Cancer #JournalOfThoracicOncology #NSCLC #OncoDaily #Oncology

Masterful presentation by Neeraj Agarwal, MD, FASCO on CONTACT-2; combination of atezolizumab and cabozantinib in pts with mCRPC shows improvement in PFS compared to second NHT. OS data immature. #GU24

Atezolizumab plus Cabozantinib for second line advanced NSCLC. No significant PFS ( 4.6 vs 4 months ) or OS ( 10.7 vs 10.5 months ) difference. Docetaxel still going strong 💪 . Aakash Desai, MD, MPH Bijoy Telivala Tejas Patil Alfredo Addeo MD Stephen V Liu, MD H. Jack West, MD M. Bolton Patrick Forde

💉🩸High serum sodium predicts response to IO in mUC and mRCC
EORTC Oncology Advance

➡️Posthoc analyses of IMvigor211 (mUC, atezolizumab) and IMmotion151 (mRCC, atezolizumab+bevacizumab) trials
✅Baseline serum sodium levels of >140mmol/L : higher objective response⬆️
✅Serum…

#GI24 ASCO Ongoing Phase III STELLAR 303 of Zanzalintinib (XL-092) plus Atezolizumab in MSS chemorefractory #crcsm
>> building up on investigator initiated effort from CAMILLA CRC cohort presented @ #GI22 ✨✨
>> looking forward to interim results in the near future.
OncoAlert

🫁 #KRAS #ICI
Drug-induced lung injury in a patient treated with prior atezolizumab and subsequent sotorasib: A case report
🔻
doi.org/10.1002/rcr2.1…

SCI member Joel W. Neal, MD, PhD & others found no significant improvement in overall survival with atezolizumab +cabozantinib vs docetaxel after checkpoint inhibitor treatment and chemotherapy in patients with metastatic #NonSmallCellLungCancer ( #NSCLC ). bit.ly/3w7DvSO

Final results of the ALEXANDRA/IMpassion030 trial presented by Heather McArthur, MD, MPH at #EBCC14

No benefit from the adition of atezolizumab to adjuvant chemotherapy in pts with TNBC

Incredible honor to have been part of this important trial!

Michail ignatiadis Shigehira Saji OncoAlert
#bcsm

Pr Pr Benoit You is presenting at ESGO #meeting « The benefit from atezolizumab in patients with a poor prognosis : suboptimal debulking surgery AND unfavorable KELIM score < 1 »

Chemotherapy plus double immunotherapy (Atezolizumab + Tiragolumab) increases survival in metastatic esophageal squamous cell carcinoma SKYSCRAPER 08 at #GI24 @OncoOncology

🔥New study compares atezolizumab plus bevacizumab vs. lenvatinib as 1st-line therapy for unresectable #HCC with PVTT:
Results show comparable OS and PFS

Full text at doi.org/10.17998/jlc.2…
대한간암학회 The Korean Liver Cancer Association

El Instituto Nacional de Higiene Rafael Rangel alerta de un lote falsificado del producto TECENTRIQ (Atezolizumab) un anticuerpo monoclonal de Laboratorios Roche, indicado para cierto tipos de cáncer

Dr. DOLORES ISLA gives a great overview of adjuvant immunotherapy for resected NSCLC at #RomeLung24 . Adjuvant atezolizumab and pembrolizumab have shown benefit but questions remain esp with regard to PDL1 negative / low. Will subcutaneous atezolizumab make a big impact here?

#LiverCancer
▶️Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study

👉doi.org/10.1111/hepr.1…

#HepatolRes #LiverTwitter Wiley Clinical Health